secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001213900-25-041082
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio Q1 net loss narrows to $9.7M; Alzheimer's Phase 2 data expected late June
--------------------------------------------------------------------------------

- Net loss $9.7M ($0.42 per share) vs $11.0M YoY; R&D expenses down to $7.6M from $8.7M.
- Cash $19.3M at March 31; raised $2.1M post-quarter via stock sale; 23.2M shares outstanding.
- Top-line results from Phase 2 Alzheimer's trial (MINDFuL) expected in second half of June.
- Plans to file BLA for CORDStrom in RDEB in early 2026; partnered with Catapult for manufacturing scale-up.
- INKmune Phase I completed, Phase II opened; safety endpoint met; trial expanded to VA Health System.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025041082/0001213900-25-041082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025041082/ea0241453-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-041082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer